Inflammatory response to cardiopulmonary bypass with enoximone or steroids in patients undergoing myocardial revascularization: A preliminary report study

International Journal of Clinical Pharmacology and Therapeutics

Volumn 47, Issue 2, 2009, Pages 78-88

  Santarpino, G ^a   Caroleo, S ^a   Onorati, Frankono ^a,b   Dimastromatteo, G ^a   Abdalla, K ^a   Amantea, B ^a   Santangelo, E ^a   Gulletta, E ^a   Renzulli, A ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b NONE   (Italy)

Author keywords

CPB; Enoximone; SIRS

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENOXIMONE; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 16; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; LACTIC ACID; METHYLPREDNISOLONE; NITRIC ACID DERIVATIVE; STEROID; TROPONIN I; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; INTERLEUKIN DERIVATIVE; PHOSPHODIESTERASE INHIBITOR;

ADULT; ANESTHESIA INDUCTION; ANTIINFLAMMATORY ACTIVITY; AORTA CLAMPING; ARTICLE; BOLUS INJECTION; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; FEMALE; HEART INDEX; HEART MUSCLE REVASCULARIZATION; HEMODYNAMICS; HUMAN; HYPERTENSION; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATION; MALE; MORBIDITY; MORTALITY; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SWAN GANZ CATHETER; SYSTEMIC VASCULAR RESISTANCE; COMPARATIVE STUDY; DRUG EFFECT; METABOLISM; MIDDLE AGED; POSTOPERATIVE COMPLICATION; PROSPECTIVE STUDY; TIME; UNIVERSITY HOSPITAL;

ANTI-INFLAMMATORY AGENTS; CARDIOPULMONARY BYPASS; ENOXIMONE; FEMALE; HEMODYNAMICS; HOSPITALS, UNIVERSITY; HUMANS; INTERFERON-GAMMA; INTERLEUKINS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; PHOSPHODIESTERASE INHIBITORS; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 62749109461     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP47078     Document Type: Article

References (41)

1. Ando M, Park IS, Wada N, Takahashi Y. Steroid supplementation: a legitimate pharmacotherapy after neonatal open heart surgery. Ann Thorac Surg. 2005; 80: 1672-1678.
2. Bergman MR, Holycross BJ. Pharmacological modulation of tumor necrosis factor-production, by phosphodiesterase inhibitors. J Pharmacol Exp Ther. 1996; 279: 247-254.
3. Boldt J, Brosch C, Suttner S, Piper SN, Lehmann A, Werling C. Prophylactic use of the phospodiesterase III inhibitor enoximone in elderly cardiac surgery patients: effect on hemodynamics, inflammation, and markers of organ function. Intens Care Med. 2002; 28: 1462-1469.
4. Cain BS, Meldrum DR, Dinarello CA, Meng X, Joo KS, Banerjee A, Harken AH. Tumor necrosis factor-α and inteleukin-1β synergistically depress human myocardial function. Crit Care Med. 1999; 27: 1309-1318.
5. Celik JB, Gormus N, Okesli S, Gormus ZI, Solak H. Methylprednisolone prevents inflammatory reaction occurring during cardiopulmonary bypass: effects on TNF-α, IL-6, IL-8, IL-10. Perfusion. 2004; 19: 185-191.
6. Chalkiadakis GE, Kostakis A, Karayannacos PE, et al. Pentoxiphylline in the treatment of experimental peritonitis in rats. Arch Surg. 1985; 120: 1141-1144.
7. Chanani NK, Cowan DB, Takeuchi K, Poutias DN, Garcia LM, del Nido PJ, McGowan FX Jr. Differential effects of amrinone and milrinone upon myocardial inflammatory signaling. Circulation. 2002; 106 (Suppl 1): I284-I289.
8. Donnelly RP, Freeman SL, Hayes MP. Inhibition of IL-10 expression by IFN-γ upregulates transcription of TNF-α in human monocytes. J Immunol. 1995; 155: 1420-1427.
9. Engelman RM, Rousou JA, Flack JE, III, Deaton DW, Kalfin R, Das DK. Influence of steroids on complement and cytokine generation after cardiopulmonary bypass. Ann Thorac Surg. 1995; 60: 801-804.
10. Giomarelli P, Scolletta S, Borrelli E, Biagioli B. Myocardial and lung injury after cardiopulmonary bypass: role of interleukin (IL)-10. Ann Thorac Surg. 2003; 76: 117-123.
11. Giroir BP, Beutler B. Effect of amrinone on tumor necrosis factor production in endotoxic shock. Circ Shock. 1992; 36: 200-207.
12. Gravlee GP, Davis RF, Kurusz M, Utley JR. Cardiopulmonary bypass, principles and practice (2nd ed). Lippincott Williams and Wilkins. 2000; Section 3, Chapter 15.
13. Hall RI, Stafford Smith M, Rocker G. The systemic inflammatory response to cardiopulmonary bypass: pathophysiological, therapeutic, and pharmacological considerations. Anesth Analg. 1997; 85: 766-782.
14. Hamamoto M, Suga M, Nakatani T, Takahashi T, Sato Y, Inamori S, Yagihara T, Kitamura S. Phosphodiesterase Type 4 inhibitor prevents acute lung injury induced by cardiopulmonary bypass in a rat model. Eur J Cardiothorac Surg. 2004; 25: 833-838.
15. Hayashida N, Tomoeda H, Oda T, Tayama E, Chihara S, Kawara T, Aoyagi S. Inhibitory effect of milrinone on cytokine production after cardiopulmonary bypass. Ann Thorac Surg. 1999; 68: 1661-1667.
16. Hennein HA, Ebba H, Rodriguez JL et al. Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. J Thorac Cardiovasc Surg. 1994; 108: 626-635.
17. Kawamura T, Inada K, Nara N, Wakusawa R, Endo S. Influence of methylprednisolone on cytokine balance during cardiac surgery. Crit Care Med. 1999; 27: 545-548.
18. Konstam MA, Cody RJ. Short-term use of intravenous milrinone for heart failure. Am J Cardiol. 1995; 75: 822-826.
19. Liakopoulos OJ, Schmitto JD, Kazmaier S, Bräuer A, Quintel M, Schoendube FA, Dörge H. Cardiopulmonary and systemic effects of methylprednisolone in patients undergoing cardiac surgery. Ann Thorac Surg. 2007; 84: 110-119b.
20. Loick HM, Mollhoff T, Berendes E, Hammel D, Van Haken H. Influence of enoximone on systemic and splanchnic oxygen utilization and endotoxin release following cardiopulmonary bypass. Intens Care Med. 1997; 23: 267-275.
21. Maharaj C, Laffey JG. New strategies to control the inflammatory response in cardiac surgery. Curr Opin Anaesthesiol. 2004; 17: 35-48.
22. Matsui S, Matsumori A, Matoba Y, Uchida A, Sasayama S. Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone: suppression of natural killer cell activity and tumor necrosis factor-α production. J Clin Invest 1994; 94: 1212-1217.
23. Matsumori A, Sasayama S. Immunomodulating agents for the management of heart failure with myocarditis and cardiomyopathy: lessons from animal experiments. Eur Heart J. 1995; 16 (Suppl.): 140-143.
24. Matsumori A, Shioi T, Yamada T, Matsui S, Sasayama S. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation. 1993; 89: 955-958.
25. Mayumi H, Zhang QW, Nakashima A et al. Synergistic immunosuppression caused by high-dose methylprednisolone and cardiopulmonary bypass. Ann Thorac Surg. 1997; 63: 129-137.
26. Meldrum DR, Donnahoo KK. Role of TNF in mediating renal insufficiency following cardiac surgery: evidence of a postbypass cardiorenal syndrome. J Surg Res. 1999; 85: 185-199.
27. Monrad ES, Baim DS, Smith HS, Lanoue AS. Milrinone, dobutamine, and nitroprusside. Circulation. 1986; 73 (Suppl. 3): 168-174.
28. Morariu AM, Loef BG, Aarts LP et al. Dexamethasone: benefit and prejudice for patients undergoing on-pump coronary artery bypass grafting: a study on myocardial, pulmonary, renal, intestinal and hepatic injury Chest. 2005; 128: 2677-2687.
29. Pai RK, Ramnarine IR, Grayson AD, Mediratta NK. The effect of chronic steroid therapy on outcomes following cardiac surgery: a propensity-matched analysis. Eur J Cardiothorac Surg. 2005; 28: 138-142.
30. Paparella D, Yau TM, Young E. Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. Eur J Cardiothorac Surg. 2002; 21: 232-244.
31. Rathmell JP, Prielipp RC, Butterworth JF, Williams E, Villamaria F, Testa L, Viscomi C, Ittleman FP, Baisden CE, Royster RL. A multicenter, randomized, blind comparison of amrinone with milrinone after elective cardiac surgery. Anesth Analg. 1998; 86: 683-690.
32. Sack FU, Reidenbach B, Dollner R, Schledt A, Gebhard MM, Hagl S. Influence of steroids on microvascular perfusion injury of the bowel induced by extracorporeal circulation. Ann Thorac Surg. 2001; 72: 1321-1326.
33. Sato Y, Hiramatsu Y, Homma S, Sato S, Onizuka M, Sakakibara Y. Phosphodiesterase Type 4 inhibition of activated polymorphonuclear leukocytes in a simulated extracorporeal circulation model. J Thorac Cardiovasc Surg. 2003; 125: 172-177.
34. Schurr UP, Zünd G, Hoerstrup SP, Grünenfelder J, Maly FE, Vogt PR, Turina MI. Preoperative administration of steroids: influence on adhesion molecules and cytokines after cardiopulmonary bypass. Ann Thorac Surg. 2001; 72: 1316-1320.
35. Shioi T, Matsumori A, Matsui S, Sasayama S. Inhibition of cytokine production by a new inotropic agent, vesnarinone, in human lymphocytes, T cell line, and monocytic cell line. Life Sci. 1994; 54: 11-16.
36. Takeuchi K, del Nido PJ, Ibrahim AE, Cao-Danh H, Friehs I, Glynn P, Poutias D, Cowan DB, McGowan FX. Vesnarinone and amrinone reduce the systemic inflammatory response syndrome. J Thorac Cardiovasc Surg. 1999; 117: 375-382.
37. Tassani P, Richter JA, Barankay A et al. Does high-dose methylprednisolone in aprotinin-treated patients attenuate the systemic inflammatory response during coronary artery bypass grafting procedures? J Cardiothorac Vasc Anesth. 1999; 13: 165-172.
38. Teoh KH, Bradley CA, Gauldie J, Burrows H. Steroid inhibition of cytokine-mediated vasodilation after warm heart surgery. Circulation. 1995; 92 (Suppl. II): II-347-II-353.
39. Verghese MW, McConnell RT, Strickland AB et al. Differential regulation of human monocyte-derived TNF and IL-1β by Type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors. J Pharmacol Exp Ther. 1995; 272: 1313-1320.
40. Worrall NK, Chang K, Lejeunne WS, Misko TP, Sullivan PM, Ferguson BT Jr, Williamson JR. TNF causes reversible in vivo systemic vascular barrier dysfunction via NO-dependent and -independent mechanisms.Am J Physiol. 1997; 273: H2565-H2574.
41. Wright EM, Sherry KM. Clinical and hemodynamic effects of milrinone in the treatment of low cardiac output after cardiac surgery. Br J Anaesthesia. 1991; 67: 585-590.